mRNA expression of complement components and regulators in rat arterial smooth muscle cells

Microbiology and Immunology

Volumn 43, Issue 6, 1999, Pages 585-593

  Li, Wenxin ^a   Tada, Toyohiro ^a   Miwa, Takashi ^a   Okada, Noriko ^a   Ito, Jin Ichi ^a   Okada, Hidechika ^a   Tateyama, Hisashi ^a   Eimoto, Tadaaki ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Artery; Complement; Complement regulator; Cytokine; Smooth muscle cell

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; MALE; MESSENGER RNA SYNTHESIS; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

EID: 0032983721     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1999.tb02445.x     Document Type: Article

References (65)

1. Andoh, A., Fujiyama, Y., Sumiyoshi, K., Sakumoto, H., Okabe, H., and Bamba, T. 1997. Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Immunology 90: 358-363.
2. Arcari, P., Martinelli, R., and Salvatore, F. 1984. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res. 12: 9179-9189.
3. Bhakdi, S., and Tranum-Jensen, J. 1987. Damage to mammalian cells by proteins that form transmembrane pores. Rev. Physiol. Biochem. Pharmacol. 107: 147-223.
4. Campbell, J.H., and Campbell, G.R. 1997. The cell biology of atherosclerosis - new developments. Aust. N. Z. J. Med. 27: 497-500.
5. Chomczynski, P., Mackey, K., Drews, R., and Wilfinger, W. 1997. DNAzol: a reagent for the rapid isolation of genomic DNA. Biotechniques 22: 550-553.
6. Cole, J.L., Housley, G.A., Jr., Dykman, T.R., MacDermott, R.P., and Atkinson, J.P. 1985. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc. Natl. Acad. Sci. U.S.A. 82: 859-863.
7. Davies. A., Simmons, D.L., Hale, G., Harrison, R.A., Tighe, H., Lachmann, P.J., and Waldmann, H.L. 1989. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170: 637.
8. Gasque, P., Fontaine, M., and Morgan, B.P. 1995. Complement expression in human brain biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154: 4726-4733.
9. Gunther, S., Alexander, R.W., Atkinson, W.J., and Gimbrone, M.A., Jr. 1982. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J. Cell. Biol. 92: 289-298.
10. Harada, R., Okada, N., Fujita, T., and Okada, H. 1990. Purification of IF5 antigen which prevents complement attack on homologous cell membranes. J. Immunol. 144: 1823-1828.
11. Haviland, D., Haviland, J.C., Fleischer, D.T., and Wetsel, R.A. 1991. Structure of the murine fifth complement component (C5) gene. J. Biol. Chem. 266: 11818-11825.
12. Hetland, G., Johnson, E., and Eskeland, T. 1987. Formation of the membrane attack complex of complement (MAC) or erythrocytes from monocyte-produced terminal complement components. Scand. J. Immunol. 25: 571-577.
13. Hetland, G., Johnson, E., Ryset, P., and Eskeland, T. 1987. Human alveolar macrophages and monocytes generate the functional classical pathway of complement in vitro. Acta Pathol. Microbiol. Immunol. Scand. 95: 117-122.
14. Hobart, M.J., Fernie, B.A., and Discipio, R.G. 1995. Structure of the human C7 gene and comparison with the C6, C8A, C8B, and C9 genes. J. Immunol. 154: 5188-5194.
15. Hsueh, W., Sun, X., Rioja, L.N., and Gonzalez-Crussi, F. 1990. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 70: 309-314.
16. Hugli, T.E., and Muller-Eberhard, H.J. 1978. Anaphylatoxins: C3a and C5a. Adv. Immunol. 26: 1-53.
17. Kulics, J., Circolo, A., Strunk, R.C., and Colten, H.R. 1994. Regulation of synthesis of complement protein C4 in human fibroblasts: cell- and gene-specific effects of cytokines and lipopolysaccharide. Immunology 82: 509-515.
18. Kumar, S., Vinci, J.M., Pytel, B.A., and Baglioni, C. 1993. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res. 53: 348-353.
19. Legoedec, J., Gasque, P., Jeanne, J.F., and Fontaine, M. 1995. Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur. J. Immunol. 25: 3460-3466.
20. Leonard, E.J., and Yoshimura, T. 1990. Human monocyte chemotactic protein 1 (MCP-1). Immunol. Today 11: 97-101.
21. Levi-Strauss, M., and Mallat, M. 1987. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J. Immunol. 139: 2361-2366.
22. Libby, P., and Hansson, G.K. 1991. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 64: 5-15.
23. Liszewski, M.K., and Atkinson, J.P. 1992. Membrane cofactor protein. Curr. Top. Microbiol. Immunol. 178: 45-60.
24. Liszewski, M.K., Farries, T.C., Lublin, D.M., Rooney, I.A., and Atkinson, J.P. 1996. Control of the complement system. Adv. Immunol. 61: 201-283.
25. Lublin, D.M., and Atkinson, J.P. 1989. Decay-accelerating factor: biochemistry, molecular biology and function. Annu. Rev. Immunol. 7: 35-58.
26. Mathison, J.C., Wolfson, E., and Uievitch, R.J. 1988. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-injury in rabbits. J. Clin. Invest. 81: 1925-1937.
27. Meri, S., Morgan, B.P., Davies, A., Davies, R.H., Olavesen, M.G., Waldmann, H., and Lachmann, P.J. 1990. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9.
28. Miwa, T., Nonaka, M., Okada, N., Wakana, S., Shiroishi, T., and Okada, H. 1998. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 48: 363-371.
29. Morgan, B.P., and Gasque, P. 1997. Extrahepatic complement biosynthesis: where, when and why? Clin. Exp. Immunol. 107: 1-7.
30. Niculescu, F., Hugo, F., Rus, H.G., Vlaicu, R., and Bhakdi, S. 1987. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin. Exp. Immunol. 69: 477-483.
31. Ogata, R.T., Rosa, P.A., and Zepf, N.E. 1989. Sequence of the gene for murine complement component C4. J. Biol. Chem. 264: 16565-16572.
32. Oglesby, T.J., Allen, C.J., Liszewski, M.K., White, D.J., and Atkinson, J.P. 1992. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J. Exp. Med. 175: 1547-1551.
33. Oin, S., LaRosa, G., Campbell, J.J., Smith-Heath, H., Kassan, N., Shi, X., Zeng, L., Buthcher, B.C., and Mackay, C.R. 1996. Expression of monocyte chemoattractant protein 1 and interleukin 8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur. J. Immunol. 26: 640-647.
34. Okada, H., Tanaka, H., and Okada, N. 1983. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur. J. Immunol. 13: 340-344.
35. Okada, N., Harada, R., Fujita, T., and Okada, H. 1989. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1: 205-208.
36. Paul, M.S., Aegerter, M., Cepek, K., Miller, M.D., and Weis, J.H. 1990. The murine complement receptor gene family III. The genomic and transcriptional complexity of the Crry and Crry-ps genes. J. Immunol. 114: 1988-1996.
37. Post, T.W., Arce, M.A., Liszewaki, M.K., Thompson, E.S., Atkinson, J.P., and Lublin, D.M. 1990. Structure of the gene for human complement protein decay accelerating factor. J. Immunol. 144: 740-744.
38. Rabinovici, R., Grace Yeh, C., Leonard, M., Griswold, D.E., DiMartino, M.J., Vernick, J., Fong, K.L., and Feuerstein, G. 1992. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J. Immunol. 149: 1744-1750.
39. Renzo, L.D., Cristofaro, M.R.D., Zicari, A., Viola, R., Pontieri, G., and Lipari, M. 1994. IFNγ and TNFα cause an increased release of C3 by murine macrophages. Immunol. Lett. 42: 167-172.
40. Rollins, S.A., Zhao, J., Ninoyima, H., and Sims, P.J. 1991. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. Immunology 146: 2345-2351.
41. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
42. Rus, H.G., Niculescu, F., Constantinescu, U., Cristea, A., and Vlaicu, R. 1986. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 61: 35-42.
43. Sack, S., Zhou, W., Campbell, R.D., and Martin, J. 1993. C3 and C4 gene expression and interferon-gamma-mediated regulation in human glomerular mesangial cells. Clin. Exp. Immunol. 93: 411-417.
44. Sakurada, C., Seno, H., Dohi, N., Takizawa, H., Nonaka, M., Okada, N., and Okada, H. 1994. Molecular cloning of the rat complement regulatory protein, 512 antigen. Biochem. Biophys. Res. Commun. 198: 819-826.
45. Seifert, P.S., and Hansson, G.K. 1989. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J. Clin. Invest. 84: 597-604.
46. Seifert, P.S., Hugo, F., Hansson, G.K., and Bhakdi, S. 1989. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. 60: 747-754.
47. Seifert, P.S., and Kazatchkine, M.D. 1988. The complement system in atherosclerosis. Atherosclerosis 73: 91-104.
48. Seifert, P.S., Roth, I., Schmiedt, W., Oelert, H., Okada, N., Okada, H., and Bhakdi, S. 1992. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 96: 135-145.
49. Seya, T., Turner, J.R., and Atkinson, J.P. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163: 837-855.
50. Sherin, N.S., Zhou, W., Adler, S., and Sacks, S.H. 1997. TNFα regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney Int. 51: 703-710.
51. Strunk, R.C., Eidlen, D.M., and Mason, R.J. 1988. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J. Clin. Invest. 81: 1419-1426.
52. Sugita, Y., Nakano, Y., and Tomita, M. 1988. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J. Biochem. 104: 633-637.
53. Takizawa, H., Okada, N., and Okada, H. 1994. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152: 3032-3038.
54. Timmerman, J.J., van der Woude, F.J., van Gijlswijk-Janssen, D.J., Verweij, C.L., van Es, L.A., and Daha, M.R. 1996. Differential expression of complements in human fetal and adult kidneys. Kidney Int. 49: 730-740.
55. Tomlinson, S., Wang, Y., Ueda, E., and Esser, A.F. 1995. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis. J. Immunol. 155: 436-444.
56. Tone, M., Walsh, L.A., and Waldmann, H. 1992. Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J. Mol. Biol. 227: 971-976.
57. Torzewski, J., Bowyer, D.E., Waltenberger, J., and Fitzsimmons, C. 1997. Processes in atherogenesis: complement activation. Atherosclerosis 132: 131-138.
58. Torzewski, J., Oldroyd, R., Lachmann, P., Fitzsimmons, C., Proudhoot, D., and Bowyer, D. 1996. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler. Thromb. Vasc. Biol. 16: 673-677.
59. Torzewski, J., Torzewski, M., Bowyer, D.E., Frohlich, M., Koenig, W., Waltenberger, J., Fitzsimmons, C., and Hombach, V. 1998. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 18: 1386-1392.
60. Torzewski, M., Klouche, M., Hock, J., Messner, M., Dorweiler, B., Torzewski, J., Gabbert, H.E., and Bhakdi, S. 1998. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler. Thromb. Vasc. Biol. 18: 369-378.
61. Ueda, Y., Nagasawa, K., Tsukamoto, H., Horiuchi, T., Nishizaka, H., Ikeda, K., and Niho, Y. 1996. Production of the third and fourth component of complement (C3, C4) by smooth muscle cells. Immunology 89: 183-188.
62. Vik, D.P., Amiguet, P., Moffat, G.J., Fey, M., Amiguet-Barras, F., Wetsel, R.A., and Tack, B.F. 1991. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 30: 1080-1085.
63. Vlaicu, R., Niculescu, F., Rus, H.G., and Cristea, A. 1985. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57: 163-177.
64. Warner, S.J.C., and Libby, P. 1989. Human vascular smooth muscle cells; target for and source of tumor necrosis factor. J. Immunol. 142: 100-109.
65. White, R.T., Damm, D., Hancock, N., Rosen, B.S., Lowell, B.B., Usher, P., Flier, J.S., and Spiegelman, B.M. 1992. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J. Biol. Chem. 267: 9210-9213.